U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07166211) titled 'Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)' on Sept. 03.
Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.
Study Start Date: Sept. 15
Study Type: INTERVENTIONAL
Condition:
Chronic Spontaneous Urticaria (CSU)
Intervention:
BIOLOGICAL: CM512 injection
subcutaneous injection
DRUG: placebo
subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Keymed Biosciences Co.Ltd
Published by HT Digital Co...